Get the Stockscreener App
70.62
3.09%
2.12
After Hours:
70.62
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $70.62, with a volume of 1.33M.
It is up +3.09% in the last 24 hours and up +7.26% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$68.50
Open:
$69.28
24h Volume:
1.33M
Relative Volume:
0.63
Market Cap:
$34.44B
Revenue:
$10.63B
Net Income/Loss:
$819.00M
P/E Ratio:
42.60
EPS:
1.6577
Net Cash Flow:
$1.59B
1W Performance:
+5.18%
1M Performance:
+7.26%
6M Performance:
-10.61%
1Y Performance:
-18.75%
1-Day Range:
$69.28
$70.66
1-Week Range:
$66.85
$70.66
52-Week Range:
$61.84
$92.55
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC vs ISRG, BDX, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
70.62 | 33.41B | 10.63B | 819.00M | 1.59B | 1.6577 |
ISRG
Intuitive Surgical Inc
|
402.33 | 137.76B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
159.93 | 42.68B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
41.11 | 33.35B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
202.76 | 28.80B | 5.54B | 1.52B | 1.74B | 10.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jan-20-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-09-26 | Downgrade | Stifel | Buy → Hold |
| Dec-11-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-21-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-20-25 | Downgrade | Deutsche Bank | Buy → Hold |
| May-14-25 | Reiterated | BTIG Research | Buy |
| Mar-28-25 | Reiterated | Needham | Buy |
| Mar-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
Alcon stock trades steady as latest earnings show margin resilience - Ad Hoc News
Alcon stock holds steady as eye-care demand supports the long-term growth story - Ad Hoc News
Systane Hydration by Alcon Inc.dry eye relief beyond the pharmacy shelf - Ad Hoc News
Alcon Inc (ALC) Shares Fall 3.1% -- What GF Score of 71 Tells In - GuruFocus
Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology - Zacks Investment Research
Systane Ultra Lubricant Eye Drops by Alcon Inc.dry-eye relief drives a global franchise - Ad Hoc News
Ophthalmology Devices Market Report Released, Includes - GlobeNewswire
Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others - GlobeNewswire Inc.
Alcon stock reflects ophthalmic focus as global eye care demand grows - ad-hoc-news.de
Alcon collaborates with RxSight to develop adjustable PCIOLs - MSN
Alcon, RxSight announce collaboration to develop adjustable presbyopia-correcting IOLs - Ophthalmology Times Europe
Systane Ultra eye drops by Alcon Inc.dry-eye relief backed by a broad product family - Ad-hoc-news.de
Alcon stock holds steady as the contact lens business anchors results - ad-hoc-news.de
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook - MSN
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook - TradingView
Alcon stock reflects steady growth as eye care demand expands - ad-hoc-news.de
Alcon stock reflects steady growth prospects as eye care demand expands globally - ad-hoc-news.de
Wall Street Analysts Predict a 27.75% Upside in Alcon (ALC): Here's What You Should Know - Yahoo Finance
Alcon Inc focuses on eye care leadership as investors watch global demand - ad-hoc-news.de
Alcon focus on eye care growth and global market presence - AD HOC NEWS
Is Alcon (SWX:ALC) Cheap Following Its RxSight Collaboration And Premium P E? - simplywall.st
Is Alcon (SWX:ALC) Undervalued After Its RxSight Collaboration? - Yahoo Finance
Can Alcon Inc. (ALC) Stock Rebound as New Eye Care Products Approach Regulatory Milestones? - Insider Monkey
Alcon Inc focuses on eye care growth and global expansion - ad-hoc-news.de
Systane Complete by Alcondry eye relief with lipid layer support - AD HOC NEWS
Alcon focuses on eye-care growth as global demand for vision treatments expands - Ad-hoc-news.de
RxSight: Alcon Deal Reshapes The Long-Term Growth Story (NASDAQ:RXST) - Seeking Alpha
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs - InvisionMag.com
More Than 2.5 Million Generic Prednisolone Acetate Eye Drops Recalled - Optometry Advisor
Alcon and RxSight partner to to develop light-adjustable PCIOLs - Eyes On Eyecare
Alcon focuses on global eye care growth as a diversified medical device leader - AD HOC NEWS
Alcon Launches UNITY® CS at COS 2026, Advancing the Next Generation of Surgical Innovation in Canada - AOL.com
RXST: Collaboration with Alcon and product innovation offset Q2 headwinds, supporting revised 2026 outlook - TradingView
Alcon, RxSight Begin Co-Developing Presbyopia-Correcting IOLs - Medical Product Outsourcing
DAILIES TOTAL1 from Alcon Inc.daily lenses engineered for all?day comfort - ad-hoc-news.de
Stifel reiterates Hold on RxSight stock, $8 target on Alcon deal By Investing.com - Investing.com South Africa
Stifel reiterates Hold on RxSight stock, $8 target on Alcon deal - Investing.com
Alcon focuses on eye care growth as a global leader - AD HOC NEWS
Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight - Yahoo Finance
Alcon focuses on eye care growth as demand for vision treatments rises - AD HOC NEWS
Alcon focuses on eye care growth as investors watch long-term trends - AD HOC NEWS
Alcon, RxSight Partner to Develop Adjustable Presbyopia-Correcting IOLs - VisionMonday.com
Alcon Silver Announces Shareholder Approval of Arrangement - Yahoo Finance
Alcon, RxSight partner on adjustable lens technology - Investing.com UK
Alcon, RxSight partner on adjustable lens technology By Investing.com - Investing.com South Africa
Alcon (ALC) Partners with RxSight for Innovative Lens Developmen - GuruFocus
ALCON AGRXSIGHT TO RECEIVE $60 MLN UPFRONT PAYMENT UNDER AGREEMENT - Moomoo
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement - The Manila Times
Alcon and RxSight team up to develop light-adjustable cataract lenses - StreetInsider
Alcon–RxSight (NASDAQ: RXST) deal adds $60M upfront plus milestones, royalties - Stock Titan
Alcon AGRxsight Could Receive up to $140 M - Moomoo
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):